Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: Results from the placement of aortic transcatheter valves (PARTNER) trial (cohort B)

Circulation

Volumn 125, Issue 9, 2012, Pages 1102-1109

  Reynolds, Matthew R ^a,b   Magnuson, Elizabeth A ^c   Wang, Kaijun ^c   Lei, Yang ^c   Vilain, Katherine ^c   Walczak, Joshua ^a   Kodali, Susheel K ^d   Lasala, John M ^e   O'Neill, William W ^f   Davidson, Charles J ^g   Smith, Craig R ^d   Leon, Martin B ^d   Cohen, David J ^c  

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^d New York Presbyterian Hospital Columbia University Medical Center   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

aortic stenosis; clinical trials; cost effectiveness; transcatheter valve therapy

Indexed keywords

AORTA STENOSIS; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; PATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPTOM; TRANSCATHETER AORTIC VALVE IMPLANTATION;

AMBULATORY CARE; AORTIC VALVE; AORTIC VALVE STENOSIS; COHORT STUDIES; COST-BENEFIT ANALYSIS; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH RESOURCES; HEART CATHETERIZATION; HEART VALVE PROSTHESIS IMPLANTATION; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; PHYSICIANS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 84863230665     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.054072     Document Type: Article

References (33)

1. Ross J, Braunwald E. Aortic stenosis. Circulation. 1968;38:61-67.
2. Turina J, Hess O, Sepulcri F, Krayenbuehl HP. Spontaneous course of aortic valve disease. Eur Heart J. 1987;8:471-483. (Pubitemid 17093278)
3. Bach DS, Cimino N, Deeb GM. Unoperated patients with severe aortic stenosis. J Am Coll Cardiol. 2007;50:2018-2019. (Pubitemid 350046335)
4. Bach DS, Siao D, Girard SE, Duvernoy C, McCallister BD Jr, Gualano SK. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk. Circ Cardiovasc Qual Outcomes. 2009;2:533-539.
5. Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, Tornos P, Gohlke-Barwolf C, Boersma E, Ravaud P, Vahanian A. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005;26:2714-2720. (Pubitemid 41746694)
6. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597-1607.
7. Goldsmith J. The impact of new technology on health costs. Health Aff (Millwood). 1994;13:80-81. (Pubitemid 24252115)
8. O'Brien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB, Normand SL, DeLong ER, Shewan CM, Dokholyan RS, Peterson ED, Edwards FH, Anderson RP. The Society of Thoracic Surgeons 2008 cardiac surgery risk models, part 2: isolated valve surgery. Ann Thorac Surg. 2009;88:S23-S42.
9. Cohen DJ, Krumholz HM, Sukin CA, Ho KK, Siegrist RB, Cleman M, Heuser RR, Brinker JA, Moses JW, Savage MP, Detre K, Leon MB, Baim DS; Stent Restenosis Study Investigators. In-hospital and 1-year economic outcomes after coronary stenting or balloon angioplasty: results from a randomized clinical trial. Circulation. 1995;92:2480-2487.
10. Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, Leon MB, Moses JW, Carrozza JP Jr, Zidar JP, Kuntz RE. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation. 2004;110:508-514. (Pubitemid 39031165)
11. Taira DA, Seto TB, Siegrist R, Cosgrove R, Berezin R, Cohen DJ. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J. 2003;145:452-458. (Pubitemid 36390491)
12. Centers for Medicare and Medicaid Services. 100% MedPAR Inpatient Hospital National Data for Fiscal Year 2008: Short Stay Inpatient Diagnosis Related Groups. http://www.cms.gov/MedicareFeeforSvc PartsAB/03-MEDPAR. asp#TopOfPage. Accessed April 11, 2010.
13. Mitchell J, Burge R, Lee A, McCall NT. Per Case Prospective Payment for Episodes of Hospital Care. Springfield, VA: US Dept of Commerce National Technical Information Service; 1995. Publication No. PB95226023.
14. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203-220. (Pubitemid 40353904)
15. Weintraub WS, Barnett P, Chen S, Hartigan P, Casperson P, O'Rourke R, Boden WE, Lewis C, Veledar E, Becker E, Culler S, Kolm P, Mahoney EM, Dunbar SB, Deaton C, O'Brien B, Goeree R, Blackhouse G, Nease R, Spertus J, Kaufman S, Teo K. Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial. Am Heart J. 2006;151:1180-1185. (Pubitemid 43866611)
16. Polsky D, Glick H. Costing and cost analysis in randomized controlled trials: caveat emptor. Pharmacoeconomics. 2009;27:179-188.
17. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253-1258. (Pubitemid 26337709)
18. Efron B. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993.
19. Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med. 2005;353:1516-1522. (Pubitemid 41400929)
20. Williams I, McIver S, Moore D, Bryan S. The use of economic evaluations in NHS decision-making: a review and empirical investigation. Health Technol Assess. 2008;12:iii, ix-x, 1-175.
21. Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making. 2002;22:417-430.
22. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: part II. Circulation. 2002;106:626-630. (Pubitemid 34827715)
23. Mark DB, Nelson CL, Anstrom KJ, Al-Khatib SM, Tsiatis AA, Cowper PA, Clapp-Channing NE, Davidson-Ray L, Poole JE, Johnson G, Anderson J, Lee KL, Bardy GH. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2006;114:135-142. (Pubitemid 44420745)
24. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471-1480. (Pubitemid 41400921)
25. Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2009;2:362-369.
26. Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008;1:12-20.
27. Clegg AJ, Scott DA, Loveman E, Colquitt J, Royle P, Bryant J. Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for people with end-stage heart failure: a systematic review and economic evaluation. Int J Technol Assess Health Care. 2007;23:261-268. (Pubitemid 46642732)
28. Reynolds MR, Magnuson EA, Lei Y, Leon MB, Smith CR, Svensson LG, Webb JG, Babaliaros VC, Bowers BS, Fearon WF, Herrmann HC, Kapadia S, Kodali S, Makkar RR, Pichard AD, Cohen DJ. Health related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. Circulation. 2011;124:1964-1972.
29. Hlatky MA, Boothroyd DB, Melsop KA, Kennedy L, Rihal C, Rogers WJ, Venkitachalam L, Brooks MM. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation. 2009;120:2550 -2558.
30. Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation. 2005;111:1106-1113. (Pubitemid 40365470)
31. Wu Y, Jin R, Gao G, Grunkemeier GL, Starr A. Cost-effectiveness of aortic valve replacement in the elderly: an introductory study. J Thorac Cardiovasc Surg. 2007;133:608-613. (Pubitemid 46274758)
32. Clark MA, Duhay F, Thompson AK, Keyes MJ, Svensson LG, Bonow RO, Stockwell BT, Cohen DJ. Five-year clinical and economic outcomes in patients with medically managed severe aortic stenosis: results from a Medicare claims analysis. J Am Coll Cardiol. 2011;57:E1304. Abstract.
33. Arias E. United States Life Tables, 2006. Vol 58, No 21. Hyattsville, MD: National Center for Health Statistics; 2010.